Sarepta Therapeutics, Inc. (SRPT) financial statements (2020 and earlier)

Company profile

Business Address 215 FIRST STREET
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:1,1341,1751,090329204211265
Cash and cash equivalents8353716001228074257
Short-term investments290803479195112137 
Other undisclosed cash, cash equivalents, and short-term investments10111111218
Restricted cash and investments   1111 7
Receivables9149295424
Inventory, net of allowances, customer advances and progress billings1711258413  
Inventory1711258413   
Prepaid expense     3 
Deposits current assets     31 
Other current assets8278372717353
Other undisclosed current assets(10)(1)(11)(11)(12)(34)(8)
Total current assets:1,4691,4261,229373225248271
Noncurrent Assets
Operating lease, right-of-use asset38
Property, plant and equipment130974338373915
Long-term investments and receivables  10    
Long-term investments  10    
Intangible assets, net (including goodwill)1212148765
Intangible assets, net (excluding goodwill)1212148765
Prepaid expense 87    
Regulated entity, other noncurrent assets  1    
Deposits noncurrent assets 63     
Restricted cash and investments 111111
Other noncurrent assets174  4420
Other undisclosed noncurrent assets 363    
Total noncurrent assets:3542167951494721
TOTAL ASSETS:1,8231,6421,308424274295292
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2541687761493623
Accounts payable6834830201218
Accrued liabilities18613469312917 
Employee-related liabilities     65
Debt  610800
Derivative instruments and hedges, liabilities      9
Deferred revenue and credits33333
Contract with customer, liability3
Other liabilities11211111
Other undisclosed current liabilities     (4) 
Total current liabilities:2651748875623736
Noncurrent Liabilities
Long-term debt and lease obligation73042142561512
Long-term debt, excluding current maturities68242142561512
Operating lease, liability48
Liabilities, other than long-term debt101666677
Deferred revenue and credits   7 
Other liabilities1016666 7
Other undisclosed noncurrent liabilities     2 
Total noncurrent liabilities:7404364301221118
Total liabilities:1,00561051987834744
Stockholders' equity
Stockholders' equity attributable to parent, including:8181,032789337190248247
Common stock0000000
Additional paid in capital3,1122,6112,0071,5031,090927790
Accumulated other comprehensive income (loss)0(0)(0)(0)(0)(0) 
Accumulated deficit(2,294)(1,579)(1,217)(1,166)(899)(679) 
Other undisclosed stockholders' equity attributable to parent      (543)
Total stockholders' equity:8181,032789337190248247
TOTAL LIABILITIES AND EQUITY:1,8231,6421,308424274295292

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues381301155511014
Revenue, net155511014
Cost of revenue(67)(30)(32)(0)   
Cost of goods and services sold   (0)   
Gross profit:314271123511014
Operating expenses(1,020)(614)(294)(272)(221)(144)(106)
Other undisclosed operating income      1
Operating loss:(706)(344)(172)(267)(220)(134)(90)
Nonoperating income (expense)(8)(19)123(1)0(2)(22)
Investment income, nonoperating772    
Other nonoperating income (expense)(0)(1)(2)(1)010
Interest and debt expense(31)(2)(6)  (0)(0)
Loss from continuing operations before equity method investments, income taxes:(745)(365)(54)(267)(220)(136)(112)
Other undisclosed income from continuing operations before income taxes3126    
Loss from continuing operations before income taxes:(714)(363)(49)(267)(220)(136)(112)
Income tax expense (benefit)(1)1(2)    
Net loss:(715)(362)(51)(267)(220)(136)(112)
Other undisclosed net income attributable to parent     00
Net loss available to common stockholders, diluted:(715)(362)(51)(267)(220)(136)(112)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(715)(362)(51)(267)(220)(136)(112)
Other comprehensive income (loss)00(0)(0)(0)(0) 
Comprehensive loss:(715)(362)(51)(267)(220)(136)(112)
Other undisclosed comprehensive income, net of tax, attributable to parent     00
Comprehensive loss, net of tax, attributable to parent:(715)(362)(51)(267)(220)(136)(112)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: